keyword
MENU ▼
Read by QxMD icon Read
search

Apremilast

keyword
https://www.readbyqxmd.com/read/29144382/treatment-approaches-to-moderate-to-severe-psoriasis
#1
REVIEW
Paolo Gisondi, Micol Del Giglio, Giampiero Girolomoni
Psoriasis is a common disease, which has a considerable impact on patients and the health care system. Treatment approaches to the disease may be various because some issues are not definitely addressed. Moreover, the therapeutic paradigms are continuously changing because of the recent approval of new treatments for psoriasis such as interleukin (IL)-17 inhibitors and apremilast. In this review, the factors influencing psoriasis severity, the indications for systemic treatments, the overall parameters to be considered in the treatment choice, life style interventions, and the recommendations for the use, screening, and monitoring of systemic therapies available including acitretin, cyclosporine, methotrexate, apremilast, adalimumab, etanercept, infliximab, secukinumab, ixekizumab, and ustekinumab are discussed...
November 16, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29132853/assessing-clinical-response-and-defining-minimal-disease-activity-in-plaque-psoriasis-with-the-physician-global-assessment-and-body-surface-area-pga%C3%A2-%C3%A3-%C3%A2-bsa-composite-tool-an-analysis-of-apremilast-phase-3-esteem-data
#2
Alice B Gottlieb, Joseph F Merola, Rongdean Chen, Eugenia Levi, Kristina Callis Duffin
No abstract text is available yet for this article.
December 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29098911/targeted-treatments-for-hidradenitis-suppurativa-a-review-of-the-current-literature-and-ongoing-clinical-trials
#3
Melody Maarouf, Ashley K Clark, Dylan E Lee, Vivian Y Shi
PURPOSE: Targeted, immune-modulating drugs are at the forefront of therapy for HS, and a comprehensive clinical trial registry is needed to facilitate data pooling and clinical efficacy comparison. MATERIALS AND METHODS: A systematic review of the ClinicalTrials.gov database was searched for planned, in-progress, completed, or terminated trials investigating the effect of targeted biologic therapies for hidradenitis suppurativa (HS). When results of RCTs were not available, case reports or series were included...
November 10, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29077585/cardiovascular-complications-of-proteasome-inhibitors-used-in-multiple-myeloma
#4
Daniel C Cole, William H Frishman
The use of proteasome inhibitors (PI) as targeted chemotherapeutics have significantly improved survival in patients with multiple myeloma (MM). However, rare and serious cardiovascular complications have occurred as a result of their use, most commonly congestive heart failure, hypertension, and arrhythmias. MM occurs in an aged population with many concurrent cardiovascular risk factors. The primary disease process also contributes to cardiovascular complications. Furthermore, many MM patients have prior exposure to cardiotoxic chemotherapy such as anthracyclines...
October 25, 2017: Cardiology in Review
https://www.readbyqxmd.com/read/29073353/trial-characteristics-as-contextual-factors-when-evaluating-targeted-therapies-in-patients-with-psoriatic-disease-a-meta-epidemiological-study
#5
Christine Ballegaard, Tanja S Jørgensen, Marie Skougaard, Vibeke Strand, Philip J Mease, Lars E Kristensen, Lene Dreyer, Alice Gottlieb, Maarten de Wit, Robin Christensen, Simon Tarp
OBJECTIVES: To assess the importance of trial characteristics as contextual factors when evaluating treatment effect of targeted therapies for patients with psoriatic disease. METHODS: We identified randomized controlled trials (RCTs) evaluating targeted therapies approved for psoriatic arthritis (PsA) and psoriasis (8 biologics and apremilast). The effect of targeted therapies was analyzed in the two psoriatic conditions combined by using drug retention as common outcome, and separately by using ACR20 for PsA and PASI75 for psoriasis...
October 26, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29068290/otezla-warts-and-all-racks-up-sales-and-eyes-blockbuster-status
#6
Thomas Reinke
Otezla-the generic name is apremilast-also exploited a new mechanism of action as the first inhibitor of phosphodiesterase 4 (PDE4) that results in increased expression of both anti-inflammatory proteins and reduced expression of their pro-inflammatory counterparts.
October 2017: Managed Care
https://www.readbyqxmd.com/read/29058302/switching-between-biological-treatments-in-psoriatic-arthritis-a-review-of-the-evidence
#7
REVIEW
Luisa Costa, Carlo Perricone, Maria Sole Chimenti, Antonio Del Puente, Paolo Caso, Rosario Peluso, Paolo Bottiglieri, Raffaele Scarpa, Francesco Caso
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy. Therapy with anti-tumor necrosis factor (TNF)-α agents represents the first therapeutic choice for moderate and severe forms; however, PsA patients can experience anti-TNFα failure, lack of efficacy, or adverse events. Several evidences exist on the effectiveness of switching among different TNFα inhibitors, and we reviewed the published data on the effectiveness of anti-TNFα first-, second- and third-line. Most of the studies report that the main reason for switching to a second anti-TNFα agent is represented by lack of efficacy (primary or secondary) and, more rarely, adverse events...
December 2017: Drugs in R&D
https://www.readbyqxmd.com/read/29055155/apremilast-for-the-treatment-of-moderate-to-severe-palmoplantar-psoriasis-results-from-a-double-blind-placebo-controlled-randomized-study
#8
R Bissonnette, R Haydey, L Rosoph, C W Lynde, M Bukhalo, J Fowler, I Delorme, A Gagné-Henley, M Gooderham, Y Poulin, K Barber, P Jenkin, I Landells, D Pariser
BACKGROUND: Palmoplantar psoriasis is a variant of psoriasis vulgaris which can severely impair quality of life. OBJECTIVES: The main objectives of this double-blind, placebo-controlled, randomized study were to assess the efficacy and impact on quality of life and work productivity of apremilast for the treatment of moderate to severe palmoplantar psoriasis. METHODS: A total of 100 patients with moderate to severe palmoplantar psoriasis were randomized to either apremilast 30mg bid or placebo for 16 weeks...
October 21, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29051036/characterization-of-disease-burden-comorbidities-and-treatment-use-in-a-large-us-based-cohort-results-from-the-corrona-psoriasis-registry
#9
Bruce Strober, Chitra Karki, Marc Mason, Ning Guo, Stacey H Holmgren, Jeffrey D Greenberg, Mark Lebwohl
BACKGROUND: Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities impacting quality of life. With the advent of new treatments, there is growing need to assess the long term safety and efficacy of treatments in a real-world setting. OBJECTIVES: The objective of the Corrona Psoriasis Registry is to study the comparative safety and efficacy of FDA approved biologic treatments. METHODS: A cross-sectional study of patients enrolled in the registry, who initiated/switched to a systemic therapy at enrollment/previous 12 months...
October 16, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29036248/apremilast-and-narrowband-ultraviolet-b-combination-therapy-for-treating-moderate-to-severe-plaque-psoriasis
#10
Jerry Bagel, Elise Nelson, Brian R Keegan
BACKGROUND: Combining narrowband UVB (NB-UVB) phototherapy with biologics has been shown to enhance the therapeutic response of plaque psoriasis patients. The objective of this study was to evaluate the effectiveness of apremilast combined with NB-UVB in patients with moderate to severe plaque psoriasis. METHODS: This was a 12-week, open-label study of 29 patients diagnosed with moderate to severe psoriasis. Patients received apremilast 30 mg twice daily, and increasing doses of NB-UVB (310-312 nm) 3 times per week for 12 weeks...
October 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29034454/successful-treatment-of-sapho-syndrome-with-apremilast
#11
S Adamo, J Nilsson, A Krebs, U Steiner, A Cozzio, L E French, A G A Kolios
Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare disease with inflammatory osteoarticular and skin involvement. The pathogenesis of SAPHO syndrome remains unclear, but evidence suggests it may be an autoinflammatory disease triggered upon exposure to infectious agents in genetically predisposed individuals. Induction of the IL-23/Th17 axis as well as neutrophil activation seem to play a key role, and therapies targeting these immunological pathways, including TNF-inhibitors, ustekinumab, secukinumab and the IL-1 inhibitor anakinra are potential treatment options that need further investigation...
October 16, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29034298/generalized-pustular-psoriasis-treated-with-apremilast-in-a-patient-with-multiple-medical-comorbidities
#12
Caleb Jeon, Mio Nakamura, Sahil Sekhon, Di Yan, Jashin J Wu, Wilson Liao, Tina Bhutani
No abstract text is available yet for this article.
November 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/29033813/recurrence-of-melanoma-after-starting-apremilast-for-psoriasis
#13
Thomas G Salopek
This is a report on a 32-year-old man with a history of two previous melanomas with concurrent plaque-type psoriasis. His history dates to 2009, when he was diagnosed with his first melanoma on the right occiput, Clark's level IV, tumor thickness 1.53 mm, nonulcerated, mitotic index 1/mm(2). He subsequently developed nodal recurrence after an initial negative sentinel lymph node biopsy and was treated with complete lymph node dissection. In 2012, he was diagnosed with a second primary melanoma on the right upper chest, Clark's level IV, tumor thickness 0...
May 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29017843/short-term-reasons-for-withdrawal-and-adverse-events-associated-with-apremilast-therapy-for-psoriasis-in-real-world-practice-compared-to-clinical-trials-a-multicenter-retrospective-study
#14
Arvin Ighani, Jorge R Georgakopoulos, Neil H Shear, Scott Walsh, Jensen Yeung
No abstract text is available yet for this article.
October 7, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28989112/a-comparison-of-apremilast-monotherapy-and-combination-therapy-for-plaque-psoriasis-in-clinical-practice-a-canadian-multicenter-retrospective-study
#15
Arvin Ighani, Jorge R Georgakopoulos, Scott Walsh, Neil H Shear, Jensen Yeung
No abstract text is available yet for this article.
October 5, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28944515/methods-report-european-s3-guideline-on-the-systemic-treatment-of-psoriasis-vulgaris-update-apremilast-and-secukinumab-edf-in-cooperation-with-eadv-and-ipc
#16
C Dressler, S Rosumeck, R N Werner, G van der Kraaij, P van Lumig, M Wakkee, P Spuls, A Nast
No abstract text is available yet for this article.
September 24, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28925560/apremilast-in-psoriasis-a-prospective-real-world-study
#17
I Vujic, R Herman, M Sanlorenzo, C Posch, B Monshi, K Rappersberger, L Richter
BACKGROUND: Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis treatment. Randomized trials have documented its efficacy and safety, but data on real-world patients are scarce. OBJECTIVES: We aim to characterize psoriasis patients treated with apremilast in a real-world setting and calculate drug survival as an important measure of efficacy and compliance. METHODS: All patients with psoriasis who received apremilast between 1 April 2015 and 19 January 2017 were evaluated every 4 weeks, and we documented: age, weight, height, smoking status, family history of psoriasis, joint involvement, previous treatments, psoriasis area severity index (PASI) scores, and the onset and duration of adverse events (AE)...
September 19, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28921458/pharmacogenetics-and-pharmacogenomics-in-moderate-to-severe-psoriasis
#18
REVIEW
María C Ovejero-Benito, Ester Muñoz-Aceituno, Alejandra Reolid, Miriam Saiz-Rodríguez, Francisco Abad-Santos, Esteban Daudén
Pharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis...
September 18, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28919705/new-insight-into-the-pathogenesis-of-nail-psoriasis-and-overview-of-treatment-strategies
#19
REVIEW
Alessandra Ventura, Mauro Mazzeo, Roberta Gaziano, Marco Galluzzo, Luca Bianchi, Elena Campione
Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population. The prevalence of nail involvement in psoriasis patients varies between 15% and 79%. While the nails represent a small portion of the body surface area, psoriasis in these areas can have a disproportionate influence on a patient's physical and psychosocial activities. Differential diagnosis between an onychomycosis and a psoriatic nail could be challenging; nevertheless, coexistence of onychomycosis and nail psoriasis also occurs and both are common disorders in the general population...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28917463/lack-of-efficacy-of-apremilast-in-9-patients-with-severe-alopecia-areata
#20
LETTER
Lucy Y Liu, Brett A King
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Dermatology
keyword
keyword
64665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"